Original language | English |
---|---|
Pages (from-to) | 3606-3610 |
Number of pages | 5 |
Journal | Blood advances |
Volume | 6 |
Issue number | 12 |
DOIs |
|
Publication status | Published - 28 Jun 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood advances, Vol. 6, No. 12, 28.06.2022, p. 3606-3610.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
AU - Iacoboni, Gloria
AU - Rejeski, Kai
AU - Villacampa, Guillermo
AU - van Doesum, Jaap A.
AU - Chiappella, Annalisa
AU - Bonifazi, Francesca
AU - Lopez-Corral, Lucia
AU - van Aalderen, Michiel
AU - Kwon, Mi
AU - Martınez-Cibrian, Nuria
AU - Bramanti, Stefania
AU - Reguera-Ortega, Juan Luis
AU - Camacho-Arteaga, Lina
AU - Schmidt, Christian
AU - Marın-Niebla, Ana
AU - Kersten, Marie Jose
AU - Garcia-Sancho, Alejandro Martin
AU - Zinzani, Pier Luigi
AU - Corradini, Paolo
AU - van Meerten, Tom
AU - Subklewe, Marion
AU - Barba, Pere
N1 - Funding Information: honoraria from BMS/Celgene, Gilead, Novartis, Janssen, and Roche. K.R. declares having received research funding and travel support from Kite/Gilead and honoraria from Novartis. G.V. reported receiving honoraria for speaker activities from Merck Sharp & Dohme and served in an advisory role for Astrazeneca. A.C. declares having participated in advisory boards for BMS, Clinigen/ SecuraBIO, Gilead-Sciences, Janssen, Roche, and Takeda; receiving honoraria for lectures from Astrazeneca, BMS, Clinigen/Secura-BIO, Gilead-Sciences, Incyte, Janssen, Novartis, Roche, and Takeda. F.B. declares having received honoraria from Jazz Pharmaceuticals, NEOVII Biothech, MSD, Novartis, Pfizer, Amgen, and Cel-gene. C.S. declares having received travel support from Kite/Gilead. MJ.K. reports honoraria from Kite, Novartis, Miltenyi Biotech, Roche, and Bristol Myers Squibb/Celgene; serves in a consultancy or advisory role for Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, and Miltenyi Biotech; received research funding from Kite, Roche, Takeda, and Celgene; and travel support from Kite, Roche, Novartis, and Miltenyi Biotech. A.M.G.-S. declares having received honoraria from Roche, BMS/Celgene, Janssen, Servier, Gilead, Takeda, Eusa Pharma, and Novartis; consulting fees from Roche, BMS/Celgene, Kyowa Kirin, Clinigen, Eusa Pharma, Novartis, Gilead, Servier, and Incyte; and research funding from Janssen. P.B. declares having received honoraria from Amgen, Celgene, Gilead, Incyte, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, and Roche; funding from the Carlos III FIS16/01433 Health Institute, Asociación Española Contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). None of the mentioned conflicts of interest were related to financing of the content of this manuscript. The remaining authors declare no competing financial interests.
PY - 2022/6/28
Y1 - 2022/6/28
UR - http://www.scopus.com/inward/record.url?scp=85132841958&partnerID=8YFLogxK
U2 - https://doi.org/10.1182/bloodadvances.2021006922
DO - https://doi.org/10.1182/bloodadvances.2021006922
M3 - Comment/Letter to the editor
C2 - 35271707
SN - 2473-9529
VL - 6
SP - 3606
EP - 3610
JO - Blood advances
JF - Blood advances
IS - 12
ER -